Training on the Modular Approach on the assessment and management of psoriatic arthritis (PsA) for dermatology units

Size: px
Start display at page:

Download "Training on the Modular Approach on the assessment and management of psoriatic arthritis (PsA) for dermatology units"

Transcription

1 Training on the Modular Approach on the assessment and management of psoriatic arthritis (PsA) for dermatology units This PsA assessment initiative is led by the UK PsA Assessment Academy and funded by AbbVie Ltd. AXHUR151220n Date of preparation: August 2015

2 Overview of PsA

3 What is PsA? Psoriatic arthritis (PsA) is a progressive disorder ranging from mild synovitis to severe progressive erosive arthropathy 1 PsA is a complex condition that involves many body areas: Skin Fingernails and toenails Peripheral joints Axial skeleton (the spine, chest and sacroiliac joint) Entire digits (dactylitis) Entheses 1. Pipitone N, et al. Rheumatol 2003; 42:

4 Prevalence of PsA The prevalence of psoriasis in the general population is estimated at 2 3%, with the prevalence of inflammatory arthritis in people with psoriasis estimated at up to 30% 1 At least 20% of people with psoriasis have severe psoriatic arthritis with progressive joint lesions 1 1. NICE Technology appraisals.ta199, August 2010.

5 Diagnosis Many patients with PsA remain undiagnosed: A European study of 1,511 patients with plaque type psoriasis attending a dermatology appointment found that 20.6% had PsA; only 3% of patients had had the diagnosis of PsA established before the study 1 PsA can progress notably within the first 2 years of disease onset 2 Dual skin and joint involvement can have a negative impact on a patient s quality of life 3 It is, therefore, critical to diagnose and commence treatment early 1. Reich K, et al. Br J Dermatol. 2009; 160: Gladman DD, et al. Ann Rheum Dis. 2005; 64 : Lee S, et al. P & T 2010; 35:

6 Diagnosis Patients may present to either a dermatology or rheumatology clinic depending on their symptoms To optimise best practice all patients with psoriasis should be screened for PsA to help prevent irreversible joint damage

7 PsA Assessment Academy Outside In recommendations are based on the expert opinion of the PsA Assessment Academy

8 Objectives of training To provide background information on PsA To explain the new Modular Approach on the assessment of PsA To ensure all practitioners are proficient in using the assessment tools To agree a standardised assessment protocol for each clinic

9 PsA Assessment Academy A group of physician and nurse experts in rheumatology and dermatology were bought together by AbbVie to discuss the assessment of PsA based on the available evidence: Bruce Kirkham, Consultant Rheumatologist, Guy s Hospital, London Philip Helliwell, Consultant Rheumatologist/Senior Lecturer, Leeds University Eleanor Korendowych, Consultant Rheumatologist, Royal National Hospital for Rheumatic Diseases, Bath Kate Gadsby, Rheumatology Consultant Nurse, AbbVie & Honorary Rheumatology Nurse Specialist, Royal Derby Hospital, Derbyshire* Sue Oliver, Past Chair RCN Rheumatology Forum and RCN Fellow. Independent Nurse Consultant Liz Parrish, Past Dermatology Lead Nurse/Matron, East Kent University Hospitals NHS Foundation Trust. Independent Nurse Consultant * Kate Gadsby works predominantly with AbbVie Ltd. But, also has a role within the NHS as an honorary rheumatology nurse specialist at Derby Hospital

10 Academy recommendations Practical recommendations were put forward that could: Optimise initial assessment and monitoring of PsA by recommending a standardised approach to assessment Improve coordination between rheumatology and dermatology services

11 Aligning with existing guidelines The recommendations were developed to build on and align with existing guidelines issued by the: British Society of Rheumatology (BSR) Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) National Institute for Clinical Excellence (NICE) Scottish Intercollegiate Guidelines Network (SIGN)

12 A Modular Approach

13 A Modular Approach Developed by the Assessment Academy, a Modular Approach was recommended which encourages sharing of knowledge and information, efficient use of time, and prompt referral and treatment of patients. As part of this approach, it has been suggested that as a minimum: Dermatology clinics should perform the PASI and the PEST. Over time the other components of the Modular Approach can be added to clinic practice

14

15 Applying the Modular Approach to daily clinical practice Agree a standardised approach for each test in your clinic All patients should be assessed for PsA Recommended assessment tools include: Dermatology Life Quality Index (DLQI) Psoriasis Area and Severity Index (PASI) Psoriasis Epidemiology Screening Tool (PEST)

16 Clinical questionnaires

17 Clinical questionnaires Clinical questionnaires can be useful for the continued management of patients who have PsA A trained receptionist or nurse can give the patient the questionnaire when the patient first arrives Clinical questionnaires should be completed periodically by the patient, or as required

18 Dermatology Life Quality Index (DLQI) The DLQI is a quality of life (QoL) measure that can be used across all skin diseases and measures different aspects of psoriasis to the PASI The DLQI consists of 10 simple questions relating to ways in which skin disease impairs lives The DLQI is calculated by summing the score of each question with a maximum of 30. The higher the score, the more quality of life is impaired

19 Dermatology Life Quality Index (DLQI) Healthcare professional pages Patient pages All Outside In materials can be downloaded from

20 Assessing the skin

21 Psoriasis Area Severity Index (PASI) PASI is an index used to express the severity of psoriasis considering the following: severity (erythema, induration and desquamation) percentage of affected area The body is assessed in four regions: Head and neck Arms Trunk (includes groin and axillae) Legs (includes buttocks) All Outside In materials can be downloaded from

22 Psoriasis Area Severity Index (PASI) Each is assigned a score to reflect extent of affected area, (0 = no skin affected, 6 = all skin affected) Severity of psoriasis is assessed with scores assigned to each of redness, thickness and scale (0= least severe, 4 = most severe) For head, arms, trunk and legs specify: The percentage of area of skin involved The severity of three clinical signs (erythema, induration and desquamation) on a scale from 0 to 4 (from none to maximum)

23 Psoriasis Area Severity Index (PASI) The PASI is the main test used in the clinic to assess total body area affected by psoriasis It can be used to monitor both the patient s psoriasis and their disease progression and response to treatment over time The test can be used to help decide the most appropriate treatment

24 Psoriasis Area Severity Index (PASI) Nails should be visually assessed for pitting during examination

25 Psoriasis Area Severity Index (PASI) All Outside In materials can be downloaded from

26 PASI score calculation Area affected was estimated to be 35% which gives an extent score 3 The total extent for the arms is 3 x 0.2 = 0.6 Severity of the plaques on the arms was calculated as 3 for erythema, 2 for scaling and induration as 2 The severity for the arms was calculated as = 7 The total extent multiplied by total severity for the arms is 0.6 x 7 = 4.2

27 PASI score calculation The calculation of the PASI for this patient is shown below:

28 Assessing the joints

29 Psoriasis Epidemiology Screening Tool (PEST) PEST should be considered for early detection of PsA Patients with psoriasis who have not been diagnosed with PsA should complete a PEST questionnaire annually Patients complete 5 questions scoring 1 point for each question answered in the affirmative All Outside In materials can be downloaded from

30 Psoriasis Epidemiology Screening Tool (PEST) The patient is also asked to show on a diagram which joints have caused them discomfort (still, swollen or painful joints) A total score of 3 or more is indicative of psoriatic arthritis and patients should be referred for further assessment by a rheumatology unit All Outside In materials can be downloaded from

31 Psoriasis Epidemiology Screening Tool (PEST) All Outside In materials can be downloaded from

32 Training materials

33 Training materials A selection of training materials are available on the Outside In website:

34 Summary Agree a standardised approach for each test in your clinic As a minimum, it has been suggested by the PsA Assessment Academy that: Dermatology clinics should perform the PASI and the PEST A total PEST score of 3 or more is indicative of psoriatic arthritis and patients should be referred for further assessment by a rheumatology unit All patients should be assessed for PsA PEST should be considered for early detection of PsA

Training on the modular approach on the assessment and management of psoriatic arthritis (PsA) for rheumatology units

Training on the modular approach on the assessment and management of psoriatic arthritis (PsA) for rheumatology units Training on the modular approach on the assessment and management of psoriatic arthritis (PsA) for rheumatology units This PsA assessment initiative is led by the UK PsA Assessment Academy and funded by

More information

Assessing Psoriatic Arthritis in your clinic

Assessing Psoriatic Arthritis in your clinic Revealing more Assessing Psoriatic Arthritis in your clinic Training manual For Trainer This PsA Assessment initiative is led by the UK PsA Assessment Academy and funded by AbbVie Ltd. Date of preparation:

More information

Use of a validated screening tool for psoriatic arthritis in dermatology clinics

Use of a validated screening tool for psoriatic arthritis in dermatology clinics BMJ Quality Improvement Reports 2015; u203335.w2644 doi: 10.1136/bmjquality.u203335.w2644 Use of a validated screening tool for psoriatic arthritis in dermatology clinics Bella Ganatra, Dishan Manoharan,

More information

EXAMINING THE CRUCIAL COALITION BETWEEN DERMATOLOGY AND RHEUMATOLOGY IN PSORIATIC ARTHRITIS

EXAMINING THE CRUCIAL COALITION BETWEEN DERMATOLOGY AND RHEUMATOLOGY IN PSORIATIC ARTHRITIS EXAMINING THE CRUCIAL COALITION BETWEEN DERMATOLOGY AND RHEUMATOLOGY IN PSORIATIC ARTHRITIS ACTIVITY 1: EARLY COLLABORATION IN THE TREATMENT OF PSA Key Slides COMMON COMORBIDITIES OF PSORIATIC DISEASE

More information

Development and Testing of New Candidate Psoriatic Arthritis Screening Questionnaires Combining Optimal Questions From Existing Tools

Development and Testing of New Candidate Psoriatic Arthritis Screening Questionnaires Combining Optimal Questions From Existing Tools Arthritis Care & Research Vol. 66, No. 9, September 2014, pp 1410 1416 DOI 10.1002/acr.22284 2014, American College of Rheumatology ORIGINAL ARTICLE Development and Testing of New Candidate Psoriatic Arthritis

More information

Psoriasis and Psoriatic Arthritis Combined Clinic Electronic Medical Records Form

Psoriasis and Psoriatic Arthritis Combined Clinic Electronic Medical Records Form Psoriasis and Psoriatic Arthritis Combined Clinic Electronic Medical Records Form NAME: AGE: SEX: CHIEF COMPLAINT: HISTORY OF PRESENT ILLNESS: The patient presents for the initial evaluation of [psoriasis

More information

Patient Reported Quality of Life in an Early Psoriatic Arthritis Cohort

Patient Reported Quality of Life in an Early Psoriatic Arthritis Cohort 26 Patient Reported Quality of Life in an Early Psoriatic Arthritis Cohort Majed Khraishi 1 2, Jennifer Hulburt, Sarah Khraishi and Courtney Youden 2 1 Memorial University of Newfoundland, St. John s,

More information

This is a repository copy of Psoriasis flare with corticosteroid use in psoriatic arthritis.

This is a repository copy of Psoriasis flare with corticosteroid use in psoriatic arthritis. This is a repository copy of Psoriasis flare with corticosteroid use in psoriatic arthritis. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/98736/ Version: Accepted Version

More information

Title: The ideal target for psoriatic arthritis? Comparison of remission and low

Title: The ideal target for psoriatic arthritis? Comparison of remission and low Title: The ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real life cohort. Leonieke J.J. van Mens, MD 1, Marleen G.H. van de Sande, MD 1, PhD 1, Arno

More information

COSENTYX (secukinumab)

COSENTYX (secukinumab) COSENTYX (secukinumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs

More information

2018 ReachMD Page 1 of 10

2018 ReachMD Page 1 of 10 Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including

More information

What is Axial Spondyloarthritis?

What is Axial Spondyloarthritis? Physiotherapist Module 2 What is Axial Spondyloarthritis? How does it apply to physiotherapists? Claire Harris, Senior Physiotherapist, London North West Healthcare NHS Trust Susan Gurden, Advanced Physiotherapy

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal (STA)

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal (STA) Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology

More information

1. Joining the Dots in Psoriatic Arthritis; 2. Reaching for a Cure for Hep C

1. Joining the Dots in Psoriatic Arthritis; 2. Reaching for a Cure for Hep C Dr Daniel Ching Consultant Rheumatologist Timaru Hospital Dr Catherine Stedman Gastroenterologist Hepatologist, Christchurch Hospital, Clinical Senior Lecturer, University Otago 7:00-8:00 Abbvie Breakfast

More information

Identification of Psoriatic Arthritis and Ankylosing Spondylitis Early Detection to Facilitate Appropriate Care

Identification of Psoriatic Arthritis and Ankylosing Spondylitis Early Detection to Facilitate Appropriate Care Identification of Psoriatic Arthritis and Ankylosing Spondylitis Early Detection to Facilitate Appropriate Care Joy Schechtman D.O. Professor Midwestern University 64C-1876207 Disclosures None 3 64C-1876207

More information

Review of the Psoriatic Arthritis working group at OMERACT 12: a report from the. GRAPPA 2014 annual meeting

Review of the Psoriatic Arthritis working group at OMERACT 12: a report from the. GRAPPA 2014 annual meeting Review of the Psoriatic Arthritis working group at OMERACT 12: a report from the GRAPPA 2014 annual meeting W. Tillett L. Eder N. Goel M. dewit A. Ogdie AM Orbai W. Campbell O. FitzGerald N. McHugh D.

More information

Certolizumab pegol (Cimzia) for psoriatic arthritis second line

Certolizumab pegol (Cimzia) for psoriatic arthritis second line Certolizumab pegol (Cimzia) for psoriatic arthritis second line This technology summary is based on information available at the time of research and a limited literature search. It is not intended to

More information

Psoriasis. Jessica Kaffenberger, M.D. Assistant Professor of Dermatology Division of Dermatology The Ohio State University Wexner Medical Center

Psoriasis. Jessica Kaffenberger, M.D. Assistant Professor of Dermatology Division of Dermatology The Ohio State University Wexner Medical Center Psoriasis Jessica Kaffenberger, M.D. Assistant Professor of Dermatology Division of Dermatology The Ohio State University Wexner Medical Center Learning objectives Recognize the different types of psoriasis

More information

Hands On PSORIATIC ARTHRITIS ITS PRESENTATION AND MANAGEMENT IN PRIMARY CARE. Introduction EDITORIAL. How common is psoriatic arthritis?

Hands On PSORIATIC ARTHRITIS ITS PRESENTATION AND MANAGEMENT IN PRIMARY CARE. Introduction EDITORIAL. How common is psoriatic arthritis? REPORTS ON THE RHEUMATIC DISEASES SERIES 6 Hands On Practical advice on management of rheumatic disease PSORIATIC ARTHRITIS ITS PRESENTATION AND MANAGEMENT IN PRIMARY CARE Philip S Helliwell Senior Lecturer

More information

A. Kopchev, S.Monov, D. Kyurkchiev, I.Ivanova, T. Georgiev (UMHAT St. Ivan Rilski, Medical University - Sofia, Bulgaria)

A. Kopchev, S.Monov, D. Kyurkchiev, I.Ivanova, T. Georgiev (UMHAT St. Ivan Rilski, Medical University - Sofia, Bulgaria) International Journal of Pharmaceutical Science Invention ISSN (Online): 2319 6718, ISSN (Print): 2319 670X Volume 6 Issue 7 July 2017 PP. 08-12 Vascular endothelial growth factor (VEGF), cartilage oligomeric

More information

Ustekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs)

Ustekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs) Ustekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs) January 2010 This technology summary is based on information available at the time of research

More information

Body Region Involvement and Quality of Life in Psoriasis: Analysis of a Randomized Controlled Trial of Adalimumab

Body Region Involvement and Quality of Life in Psoriasis: Analysis of a Randomized Controlled Trial of Adalimumab Am J Clin Dermatol (16) 17:691 699 DOI 1.7/s257-16-229-x ORIGINAL RESEARCH ARTICLE Body Region Involvement and Quality of Life in Psoriasis: Analysis of a Randomized Controlled Trial of Adalimumab April

More information

International DErmatology Outcomes Measures. Modeled after OMERACT: Outcomes Measures in Rheumatology

International DErmatology Outcomes Measures. Modeled after OMERACT: Outcomes Measures in Rheumatology International DErmatology Outcomes Measures Modeled after OMERACT: Outcomes Measures in Rheumatology 1992 original intent: obtain agreement on the minimum number of outcome measures to be included in all

More information

A Patient s Guide to. Treatments for Psoriatic Arthritis

A Patient s Guide to. Treatments for Psoriatic Arthritis A Patient s Guide to Treatments for Psoriatic Arthritis Who should read this guide? This guide is aimed at people with psoriatic arthritis (abbreviated as PsA), or those who care for a person with this

More information

Membership of Spondyloarthritis guideline Committee

Membership of Spondyloarthritis guideline Committee Membership of Committee The Committee will operate as an advisory Committee to NICE s Board developing clinical guideline on Spondyloarthritis The terms of reference and standing orders for the Committee

More information

Psoriasis, Incidence, Quality of Life, Psoriatic Arthritis, Prevalence

Psoriasis, Incidence, Quality of Life, Psoriatic Arthritis, Prevalence 1.0 Abstract Title Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients with Psoriasis Severe or Moderate with Adalimumab Treatment (TOGETHER). Keywords Psoriasis,

More information

Psoriasis and PsA Epidemiology and Classification

Psoriasis and PsA Epidemiology and Classification 5/15/15 Learning Objectives Psoriasis and PsA Epidemiology and Classification Describe epidemiology of psoriasis Examine impact of psoriasis on quality of life, work productivity, and under-treatment patterns.

More information

Ixekizumab for treating moderate to severe plaque psoriasis [ID904]

Ixekizumab for treating moderate to severe plaque psoriasis [ID904] Thank you for agreeing to make a submission on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology

More information

Information Governance

Information Governance Information Governance Dept of ehealth NHS Grampian Rosehill House Foresterhill Site Cornhill Road Aberdeen AB25 2ZG Date 12 th May 2011 Your Ref Our Ref FOI/2011/124 Enquiries to Information Governance

More information

CLOSER LOOK AT SpA. Dr. Mohamed Bedaiwi. Consultant Rheumatologist Rheumatology Unit - KKUH

CLOSER LOOK AT SpA. Dr. Mohamed Bedaiwi. Consultant Rheumatologist Rheumatology Unit - KKUH CLOSER LOOK AT SpA Dr. Mohamed Bedaiwi Consultant Rheumatologist Rheumatology Unit - KKUH Closer look at SpA I. Categories II. SIGN & SYMPTOMS III. X-RAY IV. MRI V. MANAGMENT Spondyloarthritis (SpA)

More information

Proper treatment of psoriatic arthritis (PsA) requires. Update on Treatment of Psoriatic Arthritis. Philip Mease, M.D.

Proper treatment of psoriatic arthritis (PsA) requires. Update on Treatment of Psoriatic Arthritis. Philip Mease, M.D. 167 Update on Treatment of Psoriatic Arthritis Philip Mease, M.D. Abstract Some of this past year s key papers or abstracts on psoriatic arthritis (PsA) assessment and treatment are reviewed in this paper.

More information

Clinical Practice Guideline. Psoriatic Arthritis (PsA) Version

Clinical Practice Guideline. Psoriatic Arthritis (PsA) Version Clinical Practice Guideline Psoriatic Arthritis (PsA) Version 1.1.2016 August 2016 Table of Contents Introduction...5 Diagnosis...6 Patient Assessment... 7 Management of Patients with PsA...8 Peripheral

More information

Appendix 1: Frequently Asked Questions

Appendix 1: Frequently Asked Questions Appendix 1: Frequently Asked Questions 1. What is the funding status of Inflectra (infliximab)? Effective February 25 2016, Inflectra (infliximab) will be added to the Ontario Drug Benefit (ODB) Formulary

More information

TRANSPARENCY COMMITTEE OPINION. 26 April 2006

TRANSPARENCY COMMITTEE OPINION. 26 April 2006 TRANSPARENCY COMMITTEE OPINION 26 April 2006 REMICADE 100 mg powder for concentrate for solution for infusion Box of 1 (CIP code: 562 070.1) Applicant : laboratoires Schering Plough List I Drug for hospital

More information

Content Developers. Psoriasis and PsA Clinical Features, Associated Conditions, Screening, and Assessment. Plaque Type Psoriasis. Psoriasis Phenotypes

Content Developers. Psoriasis and PsA Clinical Features, Associated Conditions, Screening, and Assessment. Plaque Type Psoriasis. Psoriasis Phenotypes Content Developers Psoriasis and PsA Clinical Features, Associated Conditions, Screening, and Assessment Amit Garg, MD Associate Professor and Founding Chair Department of Dermatology Hofstra NSLIJ School

More information

Is Methotrexate A Disease Modifying Agent In Psoriatic Arthritis?

Is Methotrexate A Disease Modifying Agent In Psoriatic Arthritis? Disclosure Statement Is Methotrexate A Disease Modifying Agent In Psoriatic Arthritis? Gabrielle H Kingsley Consultant and Reader in Rheumatology King s College London Lewisham Healthcare NHS Trust Dr

More information

Seronegative Arthropathies Guideline Scope Consultation Table 20 th May 8 th June 2014

Seronegative Arthropathies Guideline Scope Consultation Table 20 th May 8 th June 2014 National Institute for Health and Care Excellence Seronegative Arthropathies Guideline Scope Consultation Table 20 th May 8 th June 2014 AbbVie Ltd 7 The inclusion of biological disease modifying agents

More information

Pre-Activity Question 1. Psoriasis and PsA Clinical Features, Associated Conditions, Screening, and Assessment. Pre-Activity Question 2

Pre-Activity Question 1. Psoriasis and PsA Clinical Features, Associated Conditions, Screening, and Assessment. Pre-Activity Question 2 Pre-Activity Question 1 Psoriasis and PsA Clinical Features, Associated Conditions, Screening, and Assessment How confident are you in your ability to establish a clinical framework to diagnose and screen

More information

KEY MESSAGES. Psoriasis patients are more prone to cardiovascular diseases, stroke, lymphoma and non-melanoma skin cancers, and increased mortality.

KEY MESSAGES. Psoriasis patients are more prone to cardiovascular diseases, stroke, lymphoma and non-melanoma skin cancers, and increased mortality. KEY MESSAGES Psoriasis is a genetically determined, systemic immune-mediated chronic inflammatory disease that affects primarily the skin and joints. Psoriasis Vulgaris is characterised by well-demarcated

More information

Rheumatology and Internal Diseases Clinic of the Central Clinical Hospital in Warsaw 137 Woloska St. WARSAW POLAND prof. Małgorzata Wisłowska

Rheumatology and Internal Diseases Clinic of the Central Clinical Hospital in Warsaw 137 Woloska St. WARSAW POLAND prof. Małgorzata Wisłowska Rheumatology and Internal Diseases Clinic of the Central Clinical Hospital in Warsaw 137 Woloska St. WARSAW 02-507 POLAND prof. Małgorzata Wisłowska MD, PhD 1 Klinika Chorób Wewnętrznych i Reumatologii

More information

Approximately 3% of the US adult population,

Approximately 3% of the US adult population, Disease Burden and Quality of Life in Psoriasis Patients With and Without Comorbid Psoriatic Arthritis: Results From National Psoriasis Foundation Panel Surveys Emily Edson-Heredia, MPH; Baojin Zhu, PhD;

More information

apremilast 10mg, 20mg, 30mg tablets (Otezla ) SMC No. (1053/15) Celgene Ltd.

apremilast 10mg, 20mg, 30mg tablets (Otezla ) SMC No. (1053/15) Celgene Ltd. apremilast 10mg, 20mg, 30mg tablets (Otezla ) SMC No. (1053/15) Celgene Ltd. 08 May 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards

More information

Effect of Apremilast on Patient-Reported Outcomes in Patients With Moderate to Severe Plaque Psoriasis in the ESTEEM 1 Trial

Effect of Apremilast on Patient-Reported Outcomes in Patients With Moderate to Severe Plaque Psoriasis in the ESTEEM 1 Trial 1152 Effect of Apremilast on Patient-Reported Outcomes in Patients With Moderate to Severe Plaque Psoriasis in the ESTEEM 1 Trial April W. Armstrong, MD, MPH 1 ; Christopher E.M. Griffiths, MD 2 ; Tom

More information

Psoriatic arthritis (PsA) is a form of inflammatory

Psoriatic arthritis (PsA) is a form of inflammatory 243 Psoriatic Arthritis Treatment Update Philip J. Mease, M.D. Psoriatic arthritis (PsA) is a form of inflammatory arthritis that occurs in approximately 10% to 30% of individuals with psoriasis, depending

More information

Clinical application of the CASPAR criteria for psoriatic arthritis compared to other existing criteria

Clinical application of the CASPAR criteria for psoriatic arthritis compared to other existing criteria Clinical application of the CASPAR criteria for psoriatic arthritis compared to other existing criteria L. Congi 1 and E. Roussou 2 1 Rheumatology Department, Whittington Hospital, London, United Kingdom;

More information

What is Cosentyx (secukinumab)?

What is Cosentyx (secukinumab)? What is Cosentyx (secukinumab)? Cosentyx is the first of a new class of medicines called interleukin- 17A (IL- 17A) inhibitors to be approved for the treatment of moderate- to- severe plaque psoriasis,

More information

FOOT INVOLVEMENT IN PATIENTS WITH PSORIATIC ARTHRITIS: A PILOT STUDY. Cheung HY, ²Lai TL, 1 Chu H, 1 Lai KM, 1 Cheng CN, 1 Pang K, 1.

FOOT INVOLVEMENT IN PATIENTS WITH PSORIATIC ARTHRITIS: A PILOT STUDY. Cheung HY, ²Lai TL, 1 Chu H, 1 Lai KM, 1 Cheng CN, 1 Pang K, 1. FOOT INVOLVEMENT IN PATIENTS WITH PSORIATIC ARTHRITIS: A PILOT STUDY 1 Cheung HY, ²Lai TL, 1 Chu H, 1 Lai KM, 1 Cheng CN, 1 Pang K, 1 Lee F & 1 Mo SK 1 Podiatry Department, Kowloon East Cluster ²Rheumatology

More information

ETANERCEPT Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

ETANERCEPT Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL 18830 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of moderate to severe rheumatoid

More information

Visiting Professional Programme: Rheumatology

Visiting Professional Programme: Rheumatology Visiting Professional Programme: Rheumatology 1 Introduction The Guy s and St Thomas NHS Foundation Trust Rheumatology Programme is designed to provide international visiting professionals with the opportunity

More information

Why is this important for you? Types of arthritis. Information for the public Published: 28 February 2017 nice.org.uk

Why is this important for you? Types of arthritis. Information for the public Published: 28 February 2017 nice.org.uk Spondyloarthritis in over 16s: diagnosis and management Information for the public Published: 28 February 2017 nice.org.uk Spondyloarthritis: the care you should expect This information explains the care

More information

Psoriatic arthritis FACTSHEET

Psoriatic arthritis FACTSHEET 1 What is psoriatic arthritis? Psoriatic arthritis (PsA) is a disease where joints around the body become inflamed and sore. It can make moving about difficult and painful. People who have PsA also have

More information

Decision relating to the funding of TNF inhibitors (Humira and Enbrel) and gabapentin (Neurontin)

Decision relating to the funding of TNF inhibitors (Humira and Enbrel) and gabapentin (Neurontin) 9 September 2015 Decision relating to the funding of TNF inhibitors (Humira and Enbrel) and gabapentin (Neurontin) The PHARMAC Board has approved the proposal relating to the funding of the TNF-inhibitor

More information

5/4/2018. Disclosures. PsA: A heterogeneous disease. Objectives. PsA: A heterogeneous disease Fatigue

5/4/2018. Disclosures. PsA: A heterogeneous disease. Objectives. PsA: A heterogeneous disease Fatigue 5//18 Disclosures Management of Psoriatic Arthritis Alexis Ogdie, MD MSCE Assistant Professor of Medicine and Epidemiology Director, Penn Psoriatic Arthritis Clinic Division of Rheumatology Center for

More information

Comparison of comorbidities between rheumatoid and psoriatic arthritis in a tertiary care rheumatic center

Comparison of comorbidities between rheumatoid and psoriatic arthritis in a tertiary care rheumatic center Original Research Article Comparison of comorbidities between rheumatoid and psoriatic arthritis in a tertiary care rheumatic center T.N. Tamil Selvam 1, V.A. Sowndhariya 2*, N.K. Senthil Nathan 3 1 Associate

More information

Update - Imaging of the Spondyloarthropathies. Spondyloarthropathies. Spondyloarthropathies

Update - Imaging of the Spondyloarthropathies. Spondyloarthropathies. Spondyloarthropathies Update - Imaging of the Spondyloarthropathies Donald J. Flemming, M.D. Dept of Radiology Penn State Hershey Medical Center Spondyloarthropathies Family of inflammatory arthritides of synovium and entheses

More information

Health Technology Appraisal: etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (rev 104, 125)

Health Technology Appraisal: etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (rev 104, 125) Health Technology Appraisal: etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (rev 104, 125) Personal view of etanercept, infliximab and adalimumab for psoriatic arthritis

More information

Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis

Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis Axel Patrice Villani, MD, a Marie Rouzaud, MD, b Morgane Sevrain, MD, c Thomas Barnetche, PhD,

More information

Horizon Scanning Centre March Tildrakizumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 6798

Horizon Scanning Centre March Tildrakizumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 6798 Horizon Scanning Centre March 2015 Tildrakizumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 6798 This briefing is based on information available at the time of research and a limited

More information

USTEKINUMAB Generic Brand HICL GCN Exception/Other USTEKINUMAB STELARA GUIDELINES FOR USE

USTEKINUMAB Generic Brand HICL GCN Exception/Other USTEKINUMAB STELARA GUIDELINES FOR USE Generic Brand HICL GCN Exception/Other USTEKINUMAB STELARA 36187 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of psoriatic arthritis (PsA)

More information

CURRICULUM VITAE OF DR A MOORTHY. Oadby Leicester LE2 4UX.

CURRICULUM VITAE OF DR A MOORTHY. Oadby Leicester LE2 4UX. CURRICULUM VITAE OF DR A MOORTHY PERSONAL DETAILS: First Name: Surname: Address for communication: Arumugam Moorthy 12,Smore Slade Hills, Oadby Leicester LE2 4UX Telephone: 0116 271 2489 Email: Website:

More information

Jurnal Medical Aradean (Arad Medical Journal) Vol. XVIII, issue 1, 2015, pp Vasile Goldis University Press (www.jmedar.

Jurnal Medical Aradean (Arad Medical Journal) Vol. XVIII, issue 1, 2015, pp Vasile Goldis University Press (www.jmedar. Vol. XVIII, issue 1, 15, pp. 4-45 15 Vasile Goldis University Press (www.jmedar.ro) DEMOGRAPHIC AND CLINICAL PARAMETERS EVALUATION FOR PATIRNTS WITH PSORIATIC VERSUS RHEUMATOID ARTHRITIS Camelia Ciacli

More information

This is a repository copy of Methotrexate Efficacy in the Tight Control in Psoriatic Arthritis Study.

This is a repository copy of Methotrexate Efficacy in the Tight Control in Psoriatic Arthritis Study. This is a repository copy of Methotrexate Efficacy in the Tight Control in Psoriatic Arthritis Study. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/98733/ Version: Accepted

More information

Guselkumab for treating moderate to severe plaque psoriasis [ID1075]

Guselkumab for treating moderate to severe plaque psoriasis [ID1075] Guselkumab for treating moderate to severe plaque psoriasis [ID1075] Thank you for agreeing to give us your organisation s views on this technology and its possible use in the NHS. You can provide a unique

More information

THE PATIENT S PERSPECTIVE ON PSORIATIC ARTHRITIS: WHAT MORE CAN RHEUMATOLOGISTS DO TO OPTIMISE DISEASE MANAGEMENT?

THE PATIENT S PERSPECTIVE ON PSORIATIC ARTHRITIS: WHAT MORE CAN RHEUMATOLOGISTS DO TO OPTIMISE DISEASE MANAGEMENT? THE PATIENT S PERSPECTIVE ON PSORIATIC ARTHRITIS: WHAT MORE CAN RHEUMATOLOGISTS DO TO OPTIMISE DISEASE MANAGEMENT? This symposium took place on 16 th June 2017 as a part of the European League Against

More information

Differentiating Inflammatory and Mechanical Back Pain

Differentiating Inflammatory and Mechanical Back Pain This resource was organised and funded by AbbVie. It has been developed in collaboration with Claire Harris, Susan Gurden, Dr Jane Martindale, Claire Jeffries and NASS. For UK healthcare professionals

More information

Horizon Scanning Centre November Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330

Horizon Scanning Centre November Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330 Horizon Scanning Centre November 2012 Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330 Secukinumab is a high-affinity fully human monoclonal antibody that antagonises

More information

This is a repository copy of New GRAPPA and EULAR recommendations for the management of psoriatic arthritis: process and challenges faced.

This is a repository copy of New GRAPPA and EULAR recommendations for the management of psoriatic arthritis: process and challenges faced. This is a repository copy of New GRAPPA and EULAR recommendations for the management of psoriatic arthritis: process and challenges faced. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/102808/

More information

Research Developments in Psoriasis Treatment A CME Activity

Research Developments in Psoriasis Treatment A CME Activity Overview Research Developments in Psoriasis Treatment A CME Activity Mark Lebwohl, MD, Waldman Chair of Dermatology at the Icahn School of Medicine at Mount Sinai in New York, provides his perspectives

More information

P4081 Secukinumab skin clearance is associated with greater improvements in patient-reported pain, itching, and scaling

P4081 Secukinumab skin clearance is associated with greater improvements in patient-reported pain, itching, and scaling P4081 Secukinumab skin clearance is associated with greater improvements in patient-reported pain, itching, and scaling Mark Lebwohl, 1 Andrew Blauvelt, 2 Matthias Augustin, 3 Yang Zhao, 4 Isabelle Gilloteau,

More information

LCA Lung Clinical Forum. 21 st October 2014

LCA Lung Clinical Forum. 21 st October 2014 LCA Lung Clinical Forum 21 st October 2014 Welcome Dr Liz Sawicka Chair - LCA Lung Pathway Group Succession planning Dr Kate Haire Consultant in Public Health Medicine, LCA Commissioning Intentions for

More information

Psoriasis and systemic inflammation: underdiagnosed enthesopathy

Psoriasis and systemic inflammation: underdiagnosed enthesopathy DOI: 10.1111/j.1468-3083.2009.03361.x JEADV Blackwell Publishing Ltd REVIEW ARTICLE Psoriasis and systemic inflammation: underdiagnosed enthesopathy G Girolomoni*, P Gisondi Section of Dermatology and

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review Review of TA143 Adalimumab, etanercept and infliximab for ankylosing spondylitis

More information

THE UNIVERSITY OF TORONTO PSORIATIC ARTHRITIS PROGRAM JULY 2013

THE UNIVERSITY OF TORONTO PSORIATIC ARTHRITIS PROGRAM JULY 2013 THE UNIVERSITY OF TORONTO PSORIATIC ARTHRITIS PROGRAM JULY 2013 The Psoriatic Arthritis Clinic will be celebrating 35 years of Care and Research this year. The Clinic includes about 1200 patients who have

More information

Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial

Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial Original article Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial Psoriatic arthritis Philip J Mease, 1 Arthur Kavanaugh,

More information

Ontario Public Drug Programs. Inflectra (infliximab) Frequently Asked Questions

Ontario Public Drug Programs. Inflectra (infliximab) Frequently Asked Questions Ontario Public Drug Programs Inflectra (infliximab) Frequently Asked Questions 1. What is the funding status of Inflectra (infliximab)? Effective February 25 2016, Inflectra (infliximab) will be added

More information

Guidelines for the use of anti-tnfα therapy in Psoriatic Arthritis

Guidelines for the use of anti-tnfα therapy in Psoriatic Arthritis Guidelines for the use of anti-tnfα therapy in Psoriatic Arthritis 1. Active Psoriatic Arthritis 3 tender and 3 swollen joints on 2 separate occasions 1 month apart. 2. Failure of standard therapy Adequate

More information

The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment

The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment Original papers The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment Agnieszka Bożek A F, Adam Reich A F Department

More information

Cigna Drug and Biologic Coverage Policy

Cigna Drug and Biologic Coverage Policy Cigna Drug and Biologic Coverage Policy Subject Apremilast Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 4 References... 4 Effective Date... 1/1/2018 Next

More information

Juvenile Idiopathic Arthritis (JIA)

Juvenile Idiopathic Arthritis (JIA) Juvenile Idiopathic Arthritis (JIA) Kaveh Ardalan, MD, MS Division of Rheumatology Ann & Robert H. Lurie Children s Hospital of Chicago Assistant Professor, Pediatrics and Medical Social Sciences Northwestern

More information

Arthritis Rheumatism Psoriasis

Arthritis Rheumatism Psoriasis Arthritis Rheumatism Psoriasis 1 / 6 2 / 6 3 / 6 Arthritis Rheumatism Psoriasis You may think that arthritis is a single condition, but there are many forms of arthritis. Each type can be caused by different

More information

8/29/2012. Outline Juvenile idiopathic arthritis. 1. Classification-ILAR. 1. Classification-clinical diagnosis. 1. JIA classification

8/29/2012. Outline Juvenile idiopathic arthritis. 1. Classification-ILAR. 1. Classification-clinical diagnosis. 1. JIA classification Outline Juvenile idiopathic arthritis 1. Classification and symptoms (ILAR-International league of Associations for Rheumatology) 2. Imaging J. Herman Kan, M.D. Section chief, musculoskeletal imaging Edward

More information

NEW EFFECTIVE TREATMENTS FOR PSORIATIC ARTHRITIS PATIENTS Promising data to support two new drug classes

NEW EFFECTIVE TREATMENTS FOR PSORIATIC ARTHRITIS PATIENTS Promising data to support two new drug classes Annual European Congress of Rheumatology (EULAR) 2017 Madrid, Spain, 14-17 June 2017 NEW EFFECTIVE TREATMENTS FOR PSORIATIC ARTHRITIS PATIENTS Promising data to support two new drug classes Madrid, Spain,

More information

STELARA DATA SHEET NAME OF THE MEDICINE DESCRIPTION V L C L V H C H 1 C H 2 C H 3. Fab. F(ab)' 2. hinge

STELARA DATA SHEET NAME OF THE MEDICINE DESCRIPTION V L C L V H C H 1 C H 2 C H 3. Fab. F(ab)' 2. hinge DATA SHEET NAME OF THE MEDICINE Ustekinumab (rmc). CAS Registry Number: 815610-63-0. DESCRIPTION (ustekinumab) is a human IgG1kappa monoclonal antibody with an approximate molecular weight of 148,600 daltons.

More information

The Cosentyx clinical trial programme 1-11

The Cosentyx clinical trial programme 1-11 The Cosentyx clinical trial programme 1-11 There are eight pivotal trials (four in psoriasis, two in psoriatic arthritis, two in ankylosing spondylitis) There are two head-to-head trials in psoriasis showing

More information

Axial Spondyloarthritis. Doug White, Rheumatologist Waikato Hospital

Axial Spondyloarthritis. Doug White, Rheumatologist Waikato Hospital Axial Spondyloarthritis Doug White, Rheumatologist Waikato Hospital Disclosures Presentations / Consulting Abbott Laboratories AbbVie MSD Novartis Roche Clinical Trials Abbott Laboratories AbbVie Actelion

More information

Brodalumab for treating moderate to severe plaque psoriasis [ID878]

Brodalumab for treating moderate to severe plaque psoriasis [ID878] Brodalumab for treating moderate to severe plaque psoriasis [ID878] Thank you for agreeing to give us your organisation s views on this technology and its possible use in the NHS. You can provide a unique

More information

PHARMACY POLICY STATEMENT Ohio Medicaid

PHARMACY POLICY STATEMENT Ohio Medicaid DRUG NAME BILLING CODE BENEFIT TYPE SITE OF SERVICE ALLOWED COVERAGE REQUIREMENTS LIST OF DIAGNOSES CONSIDERED NOT MEDICALLY NECESSARY PHARMACY POLICY STATEMENT Ohio Medicaid Enbrel (etanercept) Must use

More information

Assessing Disease Activity in Psoriatic Arthritis: A Literature Review

Assessing Disease Activity in Psoriatic Arthritis: A Literature Review Rheumatol Ther (2019) 6:23 32 https://doi.org/10.1007/s40744-018-0132-4 REVIEW Assessing Disease Activity in Psoriatic Arthritis: A Literature Review Laura J. Tucker. Laura C. Coates. Philip S. Helliwell

More information

The 73rd Annual Meeting of the American Academy of Dermatology, San Francisco ; March 20-24, 2015 Poster ID: 909

The 73rd Annual Meeting of the American Academy of Dermatology, San Francisco ; March 20-24, 2015 Poster ID: 909 The 73rd Annual Meeting of the American Academy of Dermatology, San Francisco ; March 2-24, 215 Poster ID: 99 Clinical Efficacy and Safety of Brodalumab (KHK4827), Anti-Interleukin-17-Receptor A Fully

More information

Plantar forefoot pressures in psoriatic arthritis-related dactylitis: an exploratory study

Plantar forefoot pressures in psoriatic arthritis-related dactylitis: an exploratory study Clin Rheumatol (2016) 35:2333 2338 DOI 10.1007/s10067-016-3304-z BRIEF REPORT Plantar forefoot pressures in psoriatic arthritis-related dactylitis: an exploratory study Richard A. Wilkins 1,2 & Heidi J.

More information

THE FREQUENCY OF PSORIATIC ARTHRITIS IN PSORIATIC PATIENTS IN SULAIMANIA CITY

THE FREQUENCY OF PSORIATIC ARTHRITIS IN PSORIATIC PATIENTS IN SULAIMANIA CITY THE MEDICAL JOURNAL OF BASRAH UNIVERSITY THE FREQUENCY OF PSORIATIC ARTHRITIS IN PSORIATIC PATIENTS IN SULAIMANIA CITY Raof R. Mirza 1, Huda E. Khairulla 2 ABSTRACT Objectives: To find out the frequency

More information

DIFFERENTIATING INFLAMMATORY AND MECHANICAL BACK PAIN

DIFFERENTIATING INFLAMMATORY AND MECHANICAL BACK PAIN DIFFERENTIATING INFLAMMATORY AND MECHANICAL BACK PAIN CHALLENGE YOUR DECISION MAKING Claire Harris, Senior Physiotherapist, The North West London Hospitals NHS Trust Susan Gurden, Advanced Physiotherapy

More information

Hello, I m Christopher Ritchlin, from the University of Rochester Medical Center, and I have the pleasure today of discussing with you abstracts

Hello, I m Christopher Ritchlin, from the University of Rochester Medical Center, and I have the pleasure today of discussing with you abstracts Hello, I m Christopher Ritchlin, from the University of Rochester Medical Center, and I have the pleasure today of discussing with you abstracts presented at the 2012 American College of Rheumatology meeting

More information

Psoriasis and Psoriatic Arthritis Overview

Psoriasis and Psoriatic Arthritis Overview n REPORT n Psoriasis and Psoriatic Arthritis Overview Alan Menter, MD PSORIASIS OVERVIEW Psoriasis is a chronic, multifactorial, immune-mediated skin disease. The characteristic erythematous plaques of

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Psoriasis: the management of psoriasis 1.1 Short title Psoriasis 2 The remit The Department of Health has asked NICE: 'to produce

More information

Ustekinumab for the treatment of moderate to severe psoriasis

Ustekinumab for the treatment of moderate to severe psoriasis DOI: 10.3310/hta13suppl3/10 Health Technology Assessment 2009; Vol. 13: Suppl. 3 Ustekinumab for the treatment of moderate to severe psoriasis E Gospodarevskaya, J Picot, K Cooper, E Loveman* and A Takeda

More information

Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS.

Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology

More information

1.0 Abstract. Title P13-562

1.0 Abstract. Title P13-562 1.0 Abstract Title P13-562 Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn s Disease and Ulcerative Colitis patients`adherence attitudes to maintenance

More information

A Pilot Study. Name of investigational product:

A Pilot Study. Name of investigational product: An Open Label, Multi Center Clinical Study to Evaluate the Efficacy and Safety of a New Topical Cosmeceutical in Relieving the Redness, Scaling and Flaking Associated with Severe Skin Conditions A Pilot

More information